First National Trust Co Trims Stock Holdings in Amgen Inc. $AMGN

First National Trust Co lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 16.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,957 shares of the medical research company’s stock after selling 8,548 shares during the quarter. First National Trust Co’s holdings in Amgen were worth $12,405,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Laurel Wealth Advisors LLC raised its holdings in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after acquiring an additional 6,676,575 shares in the last quarter. Norges Bank bought a new stake in shares of Amgen in the 2nd quarter worth about $1,663,726,000. Vanguard Group Inc. raised its stake in shares of Amgen by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after purchasing an additional 841,117 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Amgen by 5.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after purchasing an additional 687,735 shares during the last quarter. Finally, Mizuho Markets Cayman LP acquired a new position in Amgen in the second quarter worth about $135,597,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Cantor Fitzgerald upped their price objective on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Daiwa Securities Group boosted their price target on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Scotiabank began coverage on Amgen in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price objective on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Finally, BMO Capital Markets increased their target price on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and a consensus price target of $351.65.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $375.82 on Tuesday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a market capitalization of $202.37 billion, a PE ratio of 26.41, a P/E/G ratio of 3.96 and a beta of 0.46. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12. The business’s fifty day moving average price is $335.21 and its two-hundred day moving average price is $311.98.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the prior year, the firm earned $5.31 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio is presently 66.90%.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 10,908 shares of company stock worth $3,674,966. Company insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.